Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Receivables - Net: 2016-2024

Historic Receivables - Net for RedHill Biopharma (RDHL) over the last 9 years, with Dec 2024 value amounting to $2.5 million.

  • RedHill Biopharma's Receivables - Net rose 449.28% to $5.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.3 million, marking a year-over-year increase of 449.28%. This contributed to the annual value of $2.5 million for FY2024, which is 2.01% down from last year.
  • Per RedHill Biopharma's latest filing, its Receivables - Net stood at $2.5 million for FY2024, which was down 2.01% from $2.6 million recorded in FY2023.
  • In the past 5 years, RedHill Biopharma's Receivables - Net ranged from a high of $34.5 million in FY2022 and a low of $2.5 million during FY2024.
  • For the 3-year period, RedHill Biopharma's Receivables - Net averaged around $13.2 million, with its median value being $2.6 million (2023).
  • Its Receivables - Net has fluctuated over the past 5 years, first soared by 2,256.50% in 2020, then plummeted by 92.49% in 2023.
  • RedHill Biopharma's Receivables - Net (Yearly) stood at $28.7 million in 2020, then increased by 10.55% to $31.7 million in 2021, then rose by 8.98% to $34.5 million in 2022, then slumped by 92.49% to $2.6 million in 2023, then declined by 2.01% to $2.5 million in 2024.